Somatropin biosimilar - CinnaGen

Drug Profile

Somatropin biosimilar - CinnaGen

Alternative Names: Cinnatropin

Latest Information Update: 04 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CinnaGen
  • Class Growth hormones; Hormonal replacements
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Growth disorders; Short stature; Somatotropin deficiency

Most Recent Events

  • 04 Aug 2017 Launched for Growth disorders (In children) in Iran (SC, 5mg/1.5ml, and 10mg/1.5ml, pre-filled pen)
  • 04 Aug 2017 Launched for Growth disorders (In children) in Iran (SC, powder for solution for injection)
  • 04 Aug 2017 Launched for Short stature (In children) in Iran (SC, 5mg/1.5ml, and 10mg/1.5ml, pre-filled pen)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top